Xolair 300 MG/2 ML autoinject 2ML
Ended Awarded
- Contract number
- SPE2DB25FUJRY
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $5,137
Award facts
- Contract value 100% obligated
- $5,136.69 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency (DLA) awarded a delivery order valued at $5,136.69 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Xolair 300 mg/2 ml auto-injector pens. This firm fixed-price delivery order, issued on September 8, 2025, with an ultimate completion date of September 29, 2025, carries no set-aside designation. Xolair (omalizumab) is a monoclonal antibody used primarily in the treatment of moderate-to-severe allergic asthma and chronic idiopathic urticaria, representing a specialty pharmaceutical product critical to military healthcare operations.
This delivery order is issued under DMS Pharmaceutical Group's existing single-award Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, which is valued at $499,999,999 and extends through November 2026. The IDC enables the DLA to procure a comprehensive range of pharmaceutical products, including branded and generic prescription drugs, biologics, and medical consumables to support medical supply needs across Department of Defense healthcare facilities worldwide. DMS Pharmaceutical Group has established itself as a significant supplier within the federal pharmaceutical supply chain, consistently securing contracts through competitive procurement based on its woman-owned small business status and demonstrated capability to deliver specialized medications and medical supplies to military health systems.
Quick answers
Who was awarded contract SPE2DB25FUJRY?
SPE2DB25FUJRY was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on September 8, 2025.
How much is contract SPE2DB25FUJRY worth?
The government has obligated $5,137 on SPE2DB25FUJRY.
Is contract SPE2DB25FUJRY an order under another contract?
Yes. SPE2DB25FUJRY is a delivery order under SPE2DB25D9365, an indefinite delivery contract.
Was contract SPE2DB25FUJRY competed?
The extent of competition for SPE2DB25FUJRY was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award